RG 6149

Drug Profile

RG 6149

Alternative Names: AMG 282; RG6149

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Class Antiasthmatics; Antibodies; Bronchodilators
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma; Rhinosinusitis

Most Recent Events

  • 31 May 2016 Amgen completes a phase I trial for Rhinosinusitis with nasal polyps in USA (NCT02170337)
  • 19 Apr 2016 AMG 282 licensed to Genentech (Roche Presentation, April 2016) before April 2016
  • 01 Mar 2016 Amgen completes enrolment in a phase I trial for Allergic asthma in USA (NCT01928368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top